CCNE1 and hypoparathyroidism-retardation-dysmorphism syndrome: We found significantly lower levels of ovaHRDscar in tumors with CCNE1 amplification, which was also previously proposed to be mutually exclusive with HRD and associated with poor clinical outcomes33.